MTTI and Monrol Have Signed a Clinical Supply Agreement for Lu-177 n.c.a.
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, for the supply of the medical radioisotope no-carrier-added 177Lu (n.c.a. 177Lu).
Eczacıbaşı-Monrol entered the theranostic market in 2019 as one of the few producers of Lutetium-177 worldwide and since then has provided an uninterrupted supply of this critical product to patients in many countries. In line with its mission to improve the quality of life of cancer patients globally, the company is establishing strategic partnerships with international pharmaceutical companies and constructing a new production facility compliant with FDA 21 CFR Part 211 quality standards that will have an annual capacity of 60 thousand doses. Thanks to its location close to Istanbul's transportation hub, the new facility will benefit from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide.
Aydin Küçük, General Manager of Eczacıbaşı-Monrol, noted that n.c.a.177Lu contributes to the company's mission of adding value to human life with leading and innovative approaches in the diagnosis and treatment of critical diseases and added, "To support our growth in this field, we're establishing a new GMP certified facility exclusively for theranostic R&D and production with a new technology that will enable us to maximize our supply of high-quality Lutetium. Sustainability and innovation are two of our core values, and we strive for continuous improvement in our operations and products while trying to serve patients all around the world."
Molecular Targeting Technologies, Inc. (MTTI) CEO, Chris Pak said, " We’ve identified a timely and sustainable supply of a key therapeutic ingredient needed for the development and launch of our lead asset 177Lu-EBTATE and other EB platform technologies. We are excited to start
this collaboration and build what promises to be a great relationship with a reliable and trusted radioisotope supply partner like Eczacıbaşı-Monrol for the supply of n.c.a.177Lu.”
About Molecular Targeting Technologies, Inc. (MTTI)
Molecular Targeting Technologies, Inc. is a privately held, rapidly growing, well financed, clinical stage biotech developing targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2022. For more information: www.mtarget.com; www.evathera.com
Eczacıbaşı-Monrol Nuclear Products Co. is an innovative, international supplier of radiopharmaceuticals for diagnosis and treatment in nuclear medicine. Eczacıbaşı-Monrol is headquartered in Istanbul and delivers customer-oriented service globally.
Monrol exports high quality and a wide spectrum of nuclear medicine products to more than 50 countries around the globe and has manufacturing sites and operational projects in different regions. For more information visit www.monrol.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Mr. Chris Pak
President & CEO
Mr. Aydın Küçük
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yokogawa Acquires PXiSE, a Developer of High-speed Control Software for Grids and Renewable Energy Assets2.12.2021 03:00:00 CET | Press release
Yokogawa Electric Corporation (TOKYO:6841) announces it has acquired all of the outstanding shares of PXiSE Energy Solutions LLC., a San Diego-based developer of software that enables utilities and other grid operators to deliver reliable and stable power by managing renewables and distributed energy resources (DERs) in real time. Through this acquisition, Yokogawa will build on its capabilities in the monitoring and control of power generation facilities and assist customers in the power transmission and distribution sectors to meet their clean energy goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005473/en/ Integration of DERs and grid components through automated grid control (Graphic: Yokogawa Electric Corporation) Renewable energy sources such as wind and solar PV are crucial for reducing greenhouse gas emissions, however the power generated is unpredictable as they are affected by the weather conditions. I
Seoul Semiconductor Supplies SunLike LED, a Natural Light Reproduction Technology, to KOIZUMI's Learning Lighting2.12.2021 01:00:00 CET | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a global optical semiconductor company, announced on the 2nd that it supplied SunLike, a natural light LED, to KOIZUMI FURNITECH Technology Corp., a Japanese learning furniture company. KOIZUMI FURNITECH, a company specializing in traditional Japanese learning furniture, is an affiliated company of Koizumi Group, same as Koizumi, a premium lighting company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005018/en/ KOIZUMI desk light (left) and children's room lighting (right) with SunLike technology (Photo: Business Wire) Seoul Semiconductor has been supplying SunLike technology to KOIZUMI lighting company. SunLike technology was already applied to KOIZUMI's children's room lighting and living room lighting in July 2020, and this time it was applied to desk light (ECL-111 and ECL-112) that helps create an optimal learning and reading environment. SunLike technology is the
Applied Risk releases new Operational Technology (OT) Security report, “Architecting the Next Generation for OT Security”2.12.2021 01:00:00 CET | Press release
Applied Risk, a leading global provider of industrial cyber security solutions, is pleased to announce the release of a new report describing current conditions in the Operational Technology (OT) Security realm and offering insight into emerging OT Security Trends. The report, entitled “Architecting the Next Generation for OT Security,” is based on data collected by the Ponemon Institute from more than 1,000 IT and OT Security practitioners (United States and Europe). The research was then complemented by input from Applied Risk’s own engagements and assessments as well as analysis by its subject matter experts (SMEs). The report notes that the sector has been shaped by factors including lower-than-ideal staff levels, the adoption of risk-based and OT-specific standards, and the failure to adopt enabling technologies. It also addresses urgent matters such as questions about ownership of OT Security Leadership, concerns about access management and the promise of new technologies such as
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results2.12.2021 00:30:00 CET | Press release
Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced today The Lancet Respiratory Medicine (“Lancet”), an internationally trusted, peer-reviewed source of clinical, public health, and global health knowledge, published positive results from Humanigen’s LIVE-AIR Phase 3 randomized, controlled trial of lenzilumab in hospitalized COVID-19 patients, as well as an independent expert commentary. The Lancet paper concludes “LIVE-AIR showed that lenzilumab treatment of hospitalised patients with COVID-19 can improve the likelihood of survival without the need for mechanical ventilation, with a safety profile similar to that of placebo.”2 “Publication of LIVE-AIR results in this peer-reviewed medical journal is a major achievement. Our goal was to demonstrate that lenzilumab, a variant-agnostic therapy, could address the unmet
Square, Inc. Changes Name to Block1.12.2021 22:30:00 CET | Press release
Square, Inc. (NYSE: SQ) announced today that it is changing its name to Block. Block will be the name for the company as a corporate entity. The Square name has become synonymous with the company’s Seller business, which provides an integrated ecosystem of commerce solutions, business software, and banking services for sellers, and this move allows the Seller business to own the Square brand it was built for. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201006139/en/ Block logo in white The change to Block acknowledges the company’s growth. Since its start in 2009, the company has added Cash App, TIDAL, and TBD54566975 as businesses, and the name change creates room for further growth. Block is an overarching ecosystem of many businesses united by their purpose of economic empowerment, and serves many people—individuals, artists, fans, developers, and sellers. “We built the Square brand for our Seller business, which is
Bentley Systems Announces the Year in Infrastructure 2021 Founders’ Honorees1.12.2021 22:01:00 CET | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the Year in Infrastructure 2021 Founders’ Honorees. During the 2021 Year in Infrastructure and Going Digital Awards virtual event today, 22 Founders’ Honorees were recognized, representing organizations or individuals whose undertakings contribute notably to infrastructure advancement and/or environmental/social development goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201006051/en/ Bentley Systems Announces the Year in Infrastructure 2021 Founders’ Honorees Bentley Systems founders Keith and Greg Bentley, and Bentley’s Director of ES(D)G Rodrigo Fernandes, reviewed the compelling credentials of 18 Honorees selected from 230 organizations who submitted nominations for the company’s annual Going Digital Awards in Infrastructure program. Chief Acceleration Officer Santanu Das recognized three Honoree organiz
CORRECTING and REPLACING: Apave, ESI Group and Onet Technologies – A unique alliance for an outstanding EPR project at the Jaitapur site in India1.12.2021 18:28:00 CET | Press release
Regulatory News: This replaces the announcement made at 3:15 PM on December 1st due to the following corrections: Last quote was cancelled. Apave, ESI Group and Onet Technologies – A unique alliance for an outstanding EPR project at the Jaitapur site in India A collaboration supported by the EDF Group and based on French complementarity and excellence. Apave, ESI Group and Onet Technologies have formalized, at the WNE (World Nuclear Exhibition) 2021, their collaboration, through the MINS (Make in India Nuclear supply chain Support) alliance, to build a common value proposition in order to respond to the project to create six EPR reactors on the Jaitapur site in western India. Philippe Maillard, CEO of APAVE Group, Emmanuel Leroy, EVP Product, Innovation & Industry Solutions of ESI Group and Alain Gauvin, CEO of ONET Technologies, signed today at WNE 2021, with the participation of Xavier Ursat, Group Senior Executive Vice President, New Nuclear Projects and Engineering, a joint declara